Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses.

PubWeight™: 1.27‹?› | Rank: Top 10%

🔗 View Article (PMC 3119210)

Published in Eur J Immunol on October 27, 2010

Authors

Brianne R Barker1, Michael N Gladstone, Geoffrey O Gillard, Michael W Panas, Norman L Letvin

Author Affiliations

1: Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Articles citing this

Expanding roles for CD4⁺ T cells in immunity to viruses. Nat Rev Immunol (2012) 2.94

An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity (2011) 2.77

Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2014) 1.16

Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with interleukin (IL)-21. PLoS Pathog (2013) 1.12

Cytokines and the inception of CD8 T cell responses. Trends Immunol (2011) 1.07

Paucity of IL-21-producing CD4(+) T cells is associated with Th17 cell depletion in SIV infection of rhesus macaques. Blood (2012) 1.07

CD4 T cells promote CD8 T cell immunity at the priming and effector site during viral encephalitis. J Virol (2011) 1.03

T cell exhaustion during persistent viral infections. Virology (2015) 1.00

Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J Clin Invest (2015) 0.93

Anti-viral CD8 T cells and the cytokines that they love. Virology (2013) 0.91

Disruption of IL-21 signaling affects T cell-B cell interactions and abrogates protective humoral immunity to malaria. PLoS Pathog (2015) 0.89

Astrocyte-derived CXCL10 drives accumulation of antibody-secreting cells in the central nervous system during viral encephalomyelitis. J Virol (2013) 0.87

Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation. BMC Pulm Med (2012) 0.85

Enhanced CD8 T-cell anti-viral function and clinical disease in B7-H1-deficient mice requires CD4 T cells during encephalomyelitis. J Neuroinflammation (2012) 0.85

Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8(+) T-cell responses and disease progression. Sci Rep (2015) 0.84

Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression. Blood (2011) 0.84

Increased IL-21 secretion by aged CD4+T cells is associated with prolonged STAT-4 activation and CMV seropositivity. Aging (Albany NY) (2012) 0.84

Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated death. Immunol Lett (2011) 0.82

α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. Acta Neuropathol Commun (2014) 0.81

Enhancement of proliferation and downregulation of TRAIL expression on CD8+ T cells by IL-21. Eur J Immunol (2010) 0.81

IL-21 optimizes T cell and humoral responses in the central nervous system during viral encephalitis. J Neuroimmunol (2013) 0.81

IL-21R expression on CD8+ T cells promotes CD8+ T cell activation in coxsackievirus B3 induced myocarditis. Exp Mol Pathol (2012) 0.81

Relationship between HBV genotypes B, C and follicular helper T cells in patients with chronic hepatitis B and its significance. Hepat Mon (2013) 0.79

A Context-Dependent Role for IL-21 in Modulating the Differentiation, Distribution, and Abundance of Effector and Memory CD8 T Cell Subsets. J Immunol (2016) 0.79

Interleukin-21 responses in patients with chronic hepatitis B. J Interferon Cytokine Res (2014) 0.79

IL-21 and T Cell Differentiation: Consider the Context. Trends Immunol (2016) 0.79

Induction of autoimmune diabetes in non-obese diabetic mice requires interleukin-21-dependent activation of autoreactive CD8⁺ T cells. Clin Exp Immunol (2013) 0.78

IL-21 Is Important for Induction of KLRG1+ Effector CD8 T Cells during Acute Intracellular Infection. J Immunol (2015) 0.77

Serum IL-21 levels associated with chronic hepatitis B and hepatitis B-related liver failure. Exp Ther Med (2014) 0.75

Interleukin-7 in Patients With Chronic Hepatitis B May Have Effect on T Follicular Helper Cells and Specific Cellular Immunity. Hepat Mon (2016) 0.75

Articles cited by this

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature (2007) 16.59

IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol (2007) 16.21

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature (2007) 14.28

Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol (2000) 12.81

Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity (2008) 9.61

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol (2004) 6.80

A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity (2008) 6.41

Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature (2006) 5.90

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86

Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med (2008) 5.71

Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med (2002) 5.64

Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell (2004) 5.59

Helping the CD8(+) T-cell response. Nat Rev Immunol (2004) 4.90

Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol (2008) 4.90

Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol (2008) 4.88

IL-21 is required to control chronic viral infection. Science (2009) 4.80

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60

A vital role for interleukin-21 in the control of a chronic viral infection. Science (2009) 4.55

IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science (2009) 3.90

CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol (2007) 3.87

CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature (2005) 3.81

IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity (2002) 3.17

CD8+ T cell contraction is controlled by early inflammation. Nat Immunol (2004) 3.13

The molecular basis of IL-21-mediated proliferation. Blood (2007) 2.90

Programming, demarcating, and manipulating CD8+ T-cell memory. Immunol Rev (2006) 2.36

Reducing the stimulation of CD8+ T cells during infection with intracellular bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset. J Immunol (2005) 1.68

Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol (2001) 1.28

IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J Immunol (2005) 1.19

The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells. J Virol (2007) 1.13

IL-21 induces apoptosis of antigen-specific CD8+ T lymphocytes. J Immunol (2007) 1.09

Overexpression of IL-21 promotes massive CD8+ memory T cell accumulation. Eur J Immunol (2007) 1.09

Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol (2006) 1.00

Unravelling the mechanisms of help for CD8+ T cell responses. Immunol Res (2009) 0.90

Evaluation of CD62L expression as a marker for vaccine-elicited memory cytotoxic T lymphocytes. Immunology (2005) 0.86

Articles by these authors

A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 7.41

Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14

T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity (2004) 3.69

Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68

Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science (2002) 3.01

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol (2005) 2.61

Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants. Nat Immunol (2005) 2.60

Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med (2006) 2.60

Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med (2010) 2.53

A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol (2005) 2.44

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol (2005) 2.40

Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol (2003) 2.39

Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol (2010) 2.39

A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain (2004) 2.37

TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLoS Pathog (2010) 2.33

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol (2007) 2.18

T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol (2009) 2.17

Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J Virol (2003) 2.15

A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog (2009) 2.09

Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol (2004) 2.09

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS (2008) 2.06

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01

Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol (2002) 1.88

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol (2004) 1.86

A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A (2008) 1.80

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol (2005) 1.78

CCL3L1 and HIV/AIDS susceptibility. Nat Med (2009) 1.73

Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog (2011) 1.70

Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. AIDS (2002) 1.69

Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol (2006) 1.63

Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol (2005) 1.63

Engineered T-cell receptor tetramers bind MHC-peptide complexes with high affinity. Nat Biotechnol (2004) 1.60

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol (2003) 1.60

Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol (2003) 1.60

Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol (2002) 1.58

Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57

Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci U S A (2004) 1.55

Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol (2003) 1.53

Immune distribution and localization of phosphoantigen-specific Vgamma2Vdelta2 T cells in lymphoid and nonlymphoid tissues in Mycobacterium tuberculosis infection. Infect Immun (2007) 1.52

Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol (2008) 1.51

Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol (2006) 1.51

Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol (2004) 1.49

T-cell dynamics during acute SIV infection. AIDS (2004) 1.46

Copy number variation of KIR genes influences HIV-1 control. PLoS Biol (2011) 1.44

Induction of an AIDS virus-related tuberculosis-like disease in macaques: a model of simian immunodeficiency virus- mycobacterium coinfection. Infect Immun (2002) 1.39

Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest (2004) 1.39

Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine (2009) 1.38

A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol (2007) 1.36

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol (2005) 1.36

Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys. J Virol (2008) 1.36

Chemical adjuvants for plasmid DNA vaccines. Vaccine (2007) 1.34

Compensatory substitutions restore normal core assembly in simian immunodeficiency virus isolates with Gag epitope cytotoxic T-lymphocyte escape mutations. J Virol (2006) 1.33

Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. AIDS (2011) 1.33

Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol (2011) 1.32

Immune gene networks of mycobacterial vaccine-elicited cellular responses and immunity. J Infect Dis (2006) 1.30

Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes. J Immunol (2005) 1.29

Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS Genet (2010) 1.28

Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol (2009) 1.28

Adaptive immune response of Vgamma2Vdelta2 T cells: a new paradigm. Trends Immunol (2003) 1.27

Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J Virol (2010) 1.26

Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. J Virol (2004) 1.25

Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol (2012) 1.24

Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine (2009) 1.24

Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys. J Virol (2005) 1.24

Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol (2004) 1.23

Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes. PLoS Pathog (2011) 1.23

Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J Virol (2011) 1.23

Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol (2006) 1.22

Immunodomination in the evolution of dominant epitope-specific CD8+ T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys. J Immunol (2006) 1.20

Clinical latency and reactivation of AIDS-related mycobacterial infections. J Virol (2004) 1.19

Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology (2007) 1.19

Vgamma2Vdelta2+ T cells and anti-microbial immune responses. Microbes Infect (2003) 1.18

Coping with viral diversity in HIV vaccine design: a response to Nickle et al. PLoS Comput Biol (2008) 1.17

Inhibition of adaptive Vgamma2Vdelta2+ T-cell responses during active mycobacterial coinfection of simian immunodeficiency virus SIVmac-infected monkeys. J Virol (2003) 1.16

HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J Virol (2011) 1.15

In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys. J Virol (2008) 1.15

Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol (2003) 1.15

The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev (2004) 1.15

Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One (2011) 1.15

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2003) 1.14

Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys. J Immunol (2002) 1.14

The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys. J Virol (2011) 1.14

Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys. J Virol (2003) 1.13

Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol (2009) 1.13

Memory CD4+ T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection. J Virol (2007) 1.13

The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells. J Virol (2007) 1.13

Monitoring HIV vaccine trial participants for primary infection: studies in the SIV/macaque model. AIDS (2009) 1.12

Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology (2012) 1.12

Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J Immunol (2006) 1.12

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol (2006) 1.11

Simian immunodeficiency virus (SIV)-specific CD8+ T-cell responses in vervet African green monkeys chronically infected with SIVagm. J Virol (2008) 1.11

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology (2006) 1.11

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol (2003) 1.10